Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of imsidolimab (ANB019) for hidradenitis suppurativa; the study has completed and results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Imsidolimab (imsidolimab)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: COMPLETED | Results posted: 2025-09-22